

H.6.1.3 Ranibizumab vs control (sham injection or PDT)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect	No of Participants	Quality of the evidence	Comments
	Corresponding risk	Assumed risk	(95% CI)	(studies)	(GRADE)	
	Ranibizumab	Control				
Gain of 15 letters or more visual acuity at one year	230 per 1000 (93 to 566)	59 per 1000	RR 3.25 (1.44 to 7.33)	1415 (4 studies)	⊕⊕⊕⊖ Moderate ¹	
Loss of fewer than 15 letters visual acuity at one year	934 per 1000 (861 to 1000)	610 per 1000	RR 1.51 (1.41 to 1.63)	1415 (4 studies)	⊕⊕⊕⊕ High	
Mean change in visual acuity at one year (number of letters)	The mean change in visual acuity in the ranibizumab groups was on average 17.80 more letters gained (95%CI 15.95 to 19.65 letters)	The mean change across control groups ranged from a loss 10 to 16 letter	MD 17.81 (15.94 to 19.67)	1322 (3 studies)	⊕⊕⊕⊕ High	
Mean change in vision-related quality of life	The mean change in vision related quality of life in the ranibizumab groups ranged from 5 to 7 points	The mean change across control groups in vision-related quality of life scores ranged from -3 to 2 points	MD 6.69 (3.38 to 9.99)	1134 (2 studies)	⊕⊕⊕⊕ High	Using the NEI-VFQ questionnaire with a 10-point difference considered as being clinically meaningful.
Serious systemic adverse events at one year	Range of 0 to 55 per 1000	Range of 5 to 83 per 1000 for various systematic adverse events	Range of RR 0.17 (0.01 to 4.24) to 2.08 (0.23 to 18.45)	603 (2 studies)		
Myocardial infarction	10 per 1000	< 10 per 1000	RR 2.08 (0.23, 18.45)	603 (2 studies)	⊕⊕⊖⊖ Low ²	


Macular Degeneration

Appendix H: Grade tables and meta-analysis results

Stroke or cerebral infarction	< 10 per 1000	< 10 per 1000	RR 1.04 (0.09, 11.38)	603 (2 studies)	⊕⊕⊕⊖ Low ²	
Treatment-emergent hypertension	60 per 1000	80 per 1000	RR 0.67 (0.36, 1.24)	603 (2 studies)	⊕⊕⊕⊖ Moderate ³	
Non-ocular hemorrhage	60 per 1000	30 per 1000	RR 1.90 (0.78, 4.62)	603 (2 studies)	⊕⊕⊕⊖ Low ²	
Serious ocular adverse events at one year	Range of 3 to 118 per 1000	Range of 0 to 68 per 1000 for various systematic adverse events	Range of RR 0.52 (0.03 to 8.25) to 2.71 (1.36 to 5.42)	603 (2 studies)		
Ocular inflammation	120 per 1000	40 per 1000	RR 2.71 (1.36 to 5.42)	603 (2 studies)	⊕⊕⊕⊕ High	
Elevated intraocular pressure (30 mmHg or more increase)	80 per 1000	30 per 1000	RR 2.22 (0.99, 4.98)	603 (2 studies)	⊕⊕⊕⊖ Moderate ³	
Cataract	100 per 1000	70 per 1000	RR 1.48 (0.83, 2.66)		⊕⊕⊕⊖ Moderate ³	
<p>*The basis for the assumed risk is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI)</p> <ol style="list-style-type: none"> 1. Downgrade one level for inconsistency due to heterogeneity ($I^2 \geq 50\%$). 2. Downgrade two levels for serious imprecision. 3. Downgrade one level for imprecision. 						

One year


Visual acuity (loss of fewer than 15 letters)



Footnotes

- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections
- (3) Control group in the PIER study received sham injections


Visual acuity (loss of fewer than 30 letters)



Footnotes

- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections


Mean change in visual acuity (number of letters)



Footnotes


- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections
- (3) Control group in the PIER study received sham injections

Quality of life score



Footnotes


- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections

Two years**Visual acuity (gain of 15 letters or more ETDRS)**Footnotes

(1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy

(2) Control group in the MARINA study received sham injections


(3) Control group in the PIER study received sham injections

Visual acuity (loss of fewer than 15 letters or more ETDRS)Footnotes

(1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy

(2) Control group in the MARINA study received sham injections


(3) Control group in the PIER study received sham injections

Visual acuity (loss of fewer than 30 letters or more ETDRS)Footnotes

(1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy

(2) Control group in the MARINA study received sham injections

Mean change in visual acuity (number of letters)




Footnotes

- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections
- (3) Control group in the PIER study received sham injections

Quality of life score

Macular Degeneration

Appendix H: Grade tables and meta-analysis results



Footnotes

- (1) Control group in the ANCHOR study received sham injections plus active verteporfin photodynamic therapy
- (2) Control group in the MARINA study received sham injections